Summary
Unable to verify alignment with any FDA-approved cyproheptadine prescribing information because no FDA label text/sections were provided; the claims are primarily about country-specific OTC/regulatory variation and are marked absent from the (non-provided) label.
Category Scores
Accurate Statements
Unsupported Statements
Cyproheptadine over-the-counter (OTC) status varies by country.
Marked as absent from the label; cannot be supported by the provided FDA labeling.
In some countries, cyproheptadine is sold OTC, while in others it requires a prescription.
Marked as absent from the label.
Some countries may limit OTC access to specific cyproheptadine products or doses.
Marked as absent from the label.
Regulatory variation for cyproheptadine reflects national drug-safety rules around antihistamines, including sedation risk.
Marked as absent from the label.
Regulatory variation for cyproheptadine reflects age restrictions.
Marked as absent from the label.
Regulatory variation for cyproheptadine reflects whether the product is considered suitable for self-selection.
Marked as absent from the label.
In countries where cyproheptadine is sold OTC, it is most often marketed as an antihistamine for allergy symptoms.
Marked as absent from the label.
In countries where cyproheptadine is sold OTC, products may be sold in fixed strengths as cough/cold or allergy formulations.
Marked as absent from the label.
OTC availability of cyproheptadine may depend on whether the product is a standalone antihistamine versus a combination product.
Marked as absent from the label.
Regulations may tighten for combination products containing antihistamines.
Marked as absent from the label.
Some markets keep cyproheptadine behind the counter due to safety issues associated with first-generation antihistamines.
Marked as absent from the label.
Safety issues associated with first-generation antihistamines include drowsiness.
Marked as absent from the label; no FDA label text provided to verify.
Safety issues associated with first-generation antihistamines include impaired driving or impaired operation of machinery.
Marked as absent from the label; no FDA label text provided to verify.
Cyproheptadine may be prescription-only in stricter markets due to risks for certain groups, including children.
Marked as absent from the label.
Cyproheptadine may be prescription-only in stricter markets due to risks for certain groups, including older adults.
Marked as absent from the label.
Cyproheptadine may be prescription-only in stricter markets due to risks for certain groups with specific medical conditions.
Marked as absent from the label.
If cyproheptadine is OTC where a patient lives, the product label includes age guidance.
Marked as absent from the label.
If cyproheptadine is OTC where a patient lives, the product label includes warnings about drowsiness.
Marked as absent from the label.
If cyproheptadine is OTC where a patient lives, the product label includes advice about driving and/or avoiding alcohol.
Marked as absent from the label.
If cyproheptadine is OTC where a patient lives, the product label indicates whether it is a single-ingredient product or combined with other active ingredients.
Marked as absent from the label.
If cyproheptadine is OTC where a patient lives, the product label specifies maximum daily dosing.
Marked as absent from the label.
Contradictions
Important Omissions
FDA-approved prescribing information content needed to assess alignment (e.g., DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, BOXED WARNING if any, WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS, USE IN SPECIFIC POPULATIONS, ADVERSE REACTIONS, and related monitoring/administration/storage details) was not provided.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims are mostly about non-FDA, country-dependent regulatory/OTC status rather than direct FDA dosing or contraindications; however, the absence of FDA label verification prevents confirming safety-relevant statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
No FDA-approved prescribing information was provided; all listed claims are marked absent from the label, so label adherence cannot be established.
Suggested Improvement
Provide the exact FDA-approved label (specific product/NDC and text for relevant sections) or paste the label content so each claim can be checked against FDA-approved statements.